Delivery Order SPE2DB22D1106-SPE2DB25FFAD0
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $1,041.42 to AmerisourceBergen Drug Corp for Repatha 140 mg/mL SureClick auto-injectors, with an ultimate completion date of July 23, 2025. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded under open competition. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract action under...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $16,727.74 to AmerisourceBergen Drug Corp for the supply of Repatha 140 mg/mL SureClick auto-injectors. The contract, designated as a firm fixed-price delivery order with no set-aside designation, was competitively awarded on August 27, 2025, with an ultimate completion date of August 28, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will fulfill this order...
- The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a $9,833.30 firm fixed-price delivery order for Repatha 140 mg/mL SureClick auto-injectors on August 25, 2025. This non-set-aside, competitively awarded contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The delivery order is scheduled for completion by August...
- The Defense Logistics Agency awarded a delivery order valued at $9,550.57 to AmerisourceBergen Drug Corp for the supply of Repatha 140 mg/ml SureClick auto-injectors, with an ultimate completion date of August 27, 2025. This competitively awarded, firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (contract SPE2DX), a $999,999,999 global pharmaceutical support vehicle running through December...
- The Defense Logistics Agency awarded a $9,811.24 delivery order to AmerisourceBergen Drug Corp for Repatha 140 mg/ml SureClick auto-injectors on September 9, 2025, with completion targeted for September 10, 2025. This non-competitive, firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. AmerisourceBergen, headquartered in...
- The Defense Logistics Agency awarded a delivery order valued at $9,080.88 to AmerisourceBergen Drug Corp for Repatha 140 mg/ml SureClick auto-injectors, with an ultimate completion date of September 2, 2025. This competitively awarded, firm fixed-price contract contains no set-aside designation and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December...
- The Defense Logistics Agency awarded a delivery order valued at $11,793.61 to AmerisourceBergen Drug Corp for Repatha 140 mg/ml SureClick auto-injectors. The contract, issued on September 11, 2025, with an ultimate completion date of September 12, 2025, is a firm fixed-price delivery order with no set-aside designation. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, performed the work at its corporate office location. This delivery...
- The Defense Logistics Agency awarded a delivery order valued at $4,719.57 to AmerisourceBergen Drug Corp on August 27, 2025, for the supply of Repatha 140 mg/mL SureClick auto-injectors. This firm fixed-price delivery order, with an ultimate completion date of August 28, 2025, represents a competitive award with no set-aside designation. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under the...
- The Defense Logistics Agency awarded a delivery order valued at $10,440.68 to AmerisourceBergen Drug Corp for the supply of Repatha 140 mg/mL SureClick auto-injectors. The contract, awarded on September 2, 2025, with an ultimate completion date of September 3, 2025, represents a firm fixed price delivery order with no set-aside designation. Performance will be executed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under the...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $34,507.05 to AmerisourceBergen Drug Corp for Repatha 140 mg/mL SureClick auto-injectors, with an ultimate completion date of September 3, 2025. This competitively awarded, firm fixed-price delivery order was issued under a non-set-aside procurement and represents a single transaction for pharmaceutical supply to support federal medical needs. The place of performance is AmerisourceBergen's corporate office in Conshohocken,...
- SPE2DB22D1106Indefinite Delivery Contract
- SPE2DB22D1106-SPE2DB25FFAD0Delivery Order
The Defense Logistics Agency has awarded a delivery order valued at $9,104.70 to AmerisourceBergen Drug Corp for the supply of Repatha 140 mg/mL SureClick auto-injectors, with an ultimate completion date of July 29, 2025. This competitively awarded, firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The primary contractor, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for federal medical procurement, particularly supporting military and veteran healthcare systems. Repatha (evolocumab) is a PCSK9 inhibitor used in the treatment of high cholesterol and cardiovascular disease, making this order part of AmerisourceBergen's comprehensive pharmaceutical supply portfolio to the Defense Health Agency and other government healthcare entities. The delivery order reflects the company's established capability to fulfill federal medical supply requirements through open competition, consistent with its extensive track record of supplying specialty medications, brand-name and generic drugs, and specialized medical devices across multiple therapeutic domains to support military healthcare programs globally.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $9.1k | 7/28/25 |